Q4 2025 Alligator Bioscience AB Earnings Call Transcript
Key Points
- Alligator Bioscience AB (STU:7AL0) published two significant papers on mitazalimab, showcasing strong clinical and mechanistic data.
- The company completed a rights issue, raising approximately SEK91 million in gross proceeds.
- Alligator Bioscience AB (STU:7AL0) strengthened its IP portfolio with a new US patent approval for its biospecific molecule ATOR-4066.
- The HLX22 molecule, developed in collaboration with Henlius, received regulatory approval in China for Phase II/III trials in HER2-positive breast cancer.
- Mitazalimab showed promising results in pancreatic cancer, with a clear dose response and several complete responders, supporting its potential in first-line therapy.
- The company is facing a short financial runway, with liquidity expected to last only until Q2 2026.
- There is uncertainty regarding the timing of milestone payments from the HLX22 program, which are dependent on study completion.
- Alligator Bioscience AB (STU:7AL0) is not in complete control of the enrollment timeline for its investigator-led studies.
- The company is still seeking partners for the phase III study of mitazalimab, which is time-consuming and uncertain.
- There is a risk of undervaluing future royalty streams if the company decides to divest its interest in HLX22 prematurely.
Hello and welcome to Alligator Biosciences 2025 year-end report call. My name is Greta Hoog. I am the IR and communications manager at Alligator, and I will be introducing today's call. With me are our CEO Søren Bregenholt and our CFO Johan Giléus.
They will walk you through the latest developments from the previous quarter and the year, as well as the upcoming news flow. After this, they will be happy to take any questions you may have. You can post them in the Q&A function of this webinar, or you can send them by email to [email protected].
As you know, Alligator Bioscience is a publicly listed company, and I'd like to note that today's presentation may include forward-looking statements. Please refer to the disclaimer on this slide, which applies to the full presentation.With the formalities out of the way, I'm handing this over to you, Søren.
¸ -
Thank you, Greta, and it's a pleasure to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
